Outcomes of palivizumab prophylaxis for respiratory syncytial virus infection in preterm children with bronchopulmonary dysplasia at a single hospital in Korea from 2005 to 2009.

Journal of Korean Medical Science
Seung Gu ChangJae Eun Yu

Abstract

This study was performed to evaluate the utilization and outcomes of palivizumab in high risk children born prematurely with chronic lung disease (CLD). A retrospective review of 128 patients was conducted from September 2004 to March 2009 at the Ajou University Hospital. All patients were diagnosed with CLD, were born at <or=35 weeks of gestation, were <2 yr old at the onset of respiratory syncytial virus (RSV) season, and had received medical therapy within six months prior to the RSV season. Fifty-three patients did not receive palivizumab prophylaxis and 75 patients received at least one dose of palivizumab. There were no statistically significant differences between the patients with and without palivizumab prophylaxis with regard to demographic characteristics and risk factors for RSV infection. There were no systemic adverse responses. Compliance with the course of prophylaxis was 92.2%. Hospitalization associated with RSV occurred in 12 cases (22.6%) in the group without prophylaxis and in three cases (4.0%) with prophylaxis. Palivizumab prophylaxis significantly reduced the frequency of RSV-related hospitalization in preterm children with CLD. This is the first retrospective review of palivizumab prophylaxis in Korea. ...Continue Reading

References

May 1, 1986·The Journal of Pediatrics·F W Denny, W A Clyde
Sep 15, 1999·Lancet·E A Simoes
Oct 12, 2000·The Journal of Infection·M R KimG M Lee
Jun 13, 2001·American Journal of Respiratory and Critical Care Medicine·A H Jobe, E Bancalari
Jun 23, 2001·The New England Journal of Medicine·C B Hall
Aug 17, 2002·The Pediatric Infectious Disease Journal·Paul I OhUNKNOWN Composs Investigators
Jan 9, 2003·JAMA : the Journal of the American Medical Association·William W ThompsonKeiji Fukuda
May 15, 2003·Pediatric Pulmonology·Curt ParnesUNKNOWN Palivizumab Outcomes Registry Study Group
Dec 5, 2003·Pediatrics·UNKNOWN American Academy of Pediatrics Committee on Infectious Diseases and Committee on Fetus and Newborn
Aug 4, 2006·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Eun Hwa ChoiJi Yeon Sung
Oct 4, 2006·Pediatrics·UNKNOWN American Academy of Pediatrics Subcommittee on Diagnosis and Management of Bronchiolitis
Oct 10, 2006·Pediatric Clinics of North America·Gerald M Loughlin, Anne Moscona
Mar 28, 2008·Journal of Perinatology : Official Journal of the California Perinatal Association·M FrogelUNKNOWN Palivizumab Outcomes Registry Group
Sep 30, 2008·Scandinavian Journal of Infectious Diseases·Yun K KimPaul E Kilgore

❮ Previous
Next ❯

Citations

Dec 31, 2014·International Journal of Pediatrics·Nusrat HomairaAdam Jaffe
Sep 13, 2016·Pediatric Pulmonology·Maria Serenella PignottiUNKNOWN Palivizumab Consensus Group
Jan 21, 2017·European Journal of Pediatrics·Daniel Y WangUNKNOWN CARESS Investigators
Nov 14, 2017·Expert Review of Respiratory Medicine·Sophie K WongBosco Paes
Nov 14, 2015·Journal of Korean Medical Science·Jang Hoon LeeUNKNOWN Committee on Data Collection and Statistical Analysis, the Korean Society of Neonatology
Nov 14, 2015·Journal of Korean Medical Science·Jang Hoon LeeUNKNOWN Committee on Data Collection and Statistical Analysis of the Korean Society of Neonatology
Feb 12, 2019·Expert Review of Anti-infective Therapy·Bosco Paes, Xavier Carbonell-Estrany
Oct 6, 2015·Paediatrics & Child Health·Joan L RobinsonUNKNOWN Canadian Paediatric Society, Infectious Diseases and Immunization Committee

❮ Previous
Next ❯

Software Mentioned

SPSS
Excel

Related Concepts

Related Feeds

Antivirals

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Antivirals (ASM)

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.